Tsonis Orestis, Gkrozou Fani, Vlachos Konstantinos, Paschopoulos Minas, Mitsis Michail C, Zakynthinakis-Kyriakou Nikolaos, Boussios Stergios, Pappas-Gogos George
Department of Obstetrics and Gynaecology, University Hospital of Ioannina, Ioannina, Greece.
Department of Obstetrics and Gynaecology, University Hospitals Birmingham, Birmingham, UK.
Ann Transl Med. 2020 Dec;8(24):1707. doi: 10.21037/atm-20-1620.
High-grade serous ovarian carcinoma (HGSOC) is a leading cause of mortality among women worldwide. Currently, there is no clear consensus over the regime these patients should receive. The main two options are upfront debulking surgery with adjuvant chemotherapy or neoadjuvant chemotherapy followed by interval debulking surgery (IDS). The former approach is proposed to be accompanied by lower chemoresistance rates but could lead to severe surgical comorbidities and lower quality of life (QoL). Optimizing patient's selection for upfront debulking surgery might offer higher progression-free and overall survival rates. Further studies need to be conducted in order to elucidate the predictive factors, which are favorable for patients undergoing upfront debulking surgery in cases of high-grade serous ovarian cancer.
高级别浆液性卵巢癌（HGSOC）是全球女性死亡的主要原因之一。目前，对于这些患者应接受的治疗方案尚无明确共识。主要的两种选择是先行减瘤手术加辅助化疗，或新辅助化疗后行中间减瘤手术（IDS）。前一种方法被认为化疗耐药率较低，但可能导致严重的手术合并症和较低的生活质量（QoL）。优化先行减瘤手术患者的选择可能会提高无进展生存率和总生存率。需要进行进一步研究以阐明预测因素，这些因素有利于高级别浆液性卵巢癌患者接受先行减瘤手术。
